Analysts predict that Insmed Incorporated (NASDAQ:INSM) will announce sales of $23.88 million for the current quarter, Zacks reports. Three analysts have provided estimates for Insmed’s earnings, with the highest sales estimate coming in at $25.70 million and the lowest estimate coming in at $22.95 million. The business is scheduled to report its next quarterly earnings results on Thursday, August 1st.
On average, analysts expect that Insmed will report full-year sales of $98.89 million for the current financial year, with estimates ranging from $94.40 million to $104.40 million. For the next year, analysts expect that the company will post sales of $176.39 million, with estimates ranging from $150.36 million to $219.36 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Insmed.
Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.02). The firm had revenue of $21.90 million during the quarter, compared to the consensus estimate of $19.61 million.
Shares of INSM traded up $0.88 during mid-day trading on Tuesday, hitting $28.56. The company’s stock had a trading volume of 514,647 shares, compared to its average volume of 907,693. Insmed has a one year low of $11.31 and a one year high of $33.13. The company has a current ratio of 4.82, a quick ratio of 6.42 and a debt-to-equity ratio of 2.48. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -6.85 and a beta of 2.98.
In related news, Director Donald J. Hayden, Jr. sold 14,900 shares of the firm’s stock in a transaction on Friday, February 22nd. The stock was sold at an average price of $28.08, for a total value of $418,392.00. Following the completion of the transaction, the director now directly owns 77,097 shares of the company’s stock, valued at $2,164,883.76. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Alfred Altomari sold 5,500 shares of the firm’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $27.50, for a total value of $151,250.00. Following the completion of the transaction, the director now directly owns 31,442 shares of the company’s stock, valued at $864,655. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,186 shares of company stock valued at $942,017. 4.95% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Insmed by 2.3% in the third quarter. Vanguard Group Inc. now owns 6,802,706 shares of the biopharmaceutical company’s stock worth $137,551,000 after purchasing an additional 154,130 shares during the period. Vanguard Group Inc lifted its holdings in shares of Insmed by 2.3% during the third quarter. Vanguard Group Inc now owns 6,802,706 shares of the biopharmaceutical company’s stock valued at $137,551,000 after acquiring an additional 154,130 shares during the period. Foresite Capital Management IV LLC lifted its holdings in shares of Insmed by 9.8% during the fourth quarter. Foresite Capital Management IV LLC now owns 1,977,236 shares of the biopharmaceutical company’s stock valued at $25,941,000 after acquiring an additional 176,649 shares during the period. Vivo Capital LLC bought a new position in shares of Insmed during the first quarter valued at $34,020,000. Finally, Northern Trust Corp lifted its holdings in shares of Insmed by 1.0% during the first quarter. Northern Trust Corp now owns 948,654 shares of the biopharmaceutical company’s stock valued at $27,577,000 after acquiring an additional 9,033 shares during the period.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Further Reading: The mechanics of the bid-ask spread in trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.